TERMINATED

Phase II Trial of Venetoclax and Rituximab as Initial Therapy in Older Patients With Mantle Cell Lymphoma

Talk to us

Conditions

Mantle Cell Lymphoma

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The proposed study is an open-label, single arm phase II study of venetoclax in combination with rituximab in patients over the age of 60 with previously untreated mantle cell lymphoma. The primary objective of the trial is to determine whether the combination of venetoclax with rituximab in this patient population yields a clinically acceptable proportion of overall responses (ORR, assessed by PET/CT with Lugano criteria) without chemotherapy.

Official Title

Phase II Trial of Venetoclax and Rituximab as Initial Therapy in Older Patients With Mantle Cell Lymphoma

Quick Facts

Study Start:2022-06-21
Study Completion:2025-05-14
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:TERMINATED

Study ID

NCT05025423

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:60 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Subjects must have a histologically confirmed diagnosis of mantle cell lymphoma as defined by the World Health Organization (WHO) classification scheme.
  2. * Age ≥ 60
  3. * Subjects must be previously untreated for mantle cell lymphoma and deemed to require treatment by the treating physician
  4. * ECOG performance status of 0-3
  5. * Subject must have adequate bone marrow\* without growth factor support as follows:
  6. * Absolute Neutrophil Count (ANC) ≥ 1000/μL
  7. * Platelets ≥ 75,000/mm3 (entry platelet count must be independent of transfusion within 14 days of Screening)
  8. * Hemoglobin ≥ 9.0 g/dL \* These criteria may be waived by study investigators if there is evidence of bone marrow involvement by MCL that is believed to be the cause of the cytopenias.
  9. * Subject must have adequate renal, and hepatic function, per laboratory reference range at screening as follows:
  10. * Subject must have adequate renal, and hepatic function, per laboratory reference range at screening as follows:
  11. * Calculated creatinine clearance ≥ 40 mL/min; determined via the Cockcroft-Gault formula.
  12. * AST and ALT ≤ 3.0 × ULN; Bilirubin ≤ 1.5 × ULN\*. Subjects with Gilbert's Syndrome may have a bilirubin \> 1.5 × ULN
  13. * These criteria may be waived by study investigators if abnormal values believed to be due to lymphoma.
  14. * Female subjects must be surgically sterile, postmenopausal (for at least 1 year), or have negative results for a pregnancy test performed as follows:
  15. * At Screening on a serum sample obtained within 14 days prior to the first study drug administration, and
  16. * Prior to dosing on a urine sample obtained on Cycle 1 Day 1 if it has been \> 7 days since obtaining the serum pregnancy test results.
  17. * All female subjects not surgically sterile or postmenopausal (for at least 1 year) and non-vasectomized male subjects must practice at least 1 of the following methods of birth control:
  18. 1. Total abstinence from sexual intercourse (minimum 1 complete menstrual cycle);
  19. 2. A vasectomized partner(s);
  20. 3. Hormonal contraceptives (oral, parenteral, vaginal ring or transdermal) for at least 3 months prior to study drug administration;
  21. 4. Double-barrier method (condoms and diaphragm with spermicidal \[sponge, jellies or creams\]).
  22. * Ability to understand and willingness to sign IRB-approved informed consent
  1. * Subject has blastoid-variant mantle cell lymphoma
  2. * Subject requires immediate cytoreduction as determined by study investigators
  3. * Subject has documented CNS involvement of mantle cell lymphoma
  4. * Subject has Ann Arbor stage I or contiguous stage II mantle cell lymphoma
  5. * Subject has an uncontrolled infection
  6. * Subject has HIV infection
  7. * All subjects will be screened for Hepatitis B (HBsAg, anti-HBs, anti-HBc IgM and total) and Hepatitis C (antibody or RNA). Subjects who are positive for Hepatitis B by HBsAg or DNA as well as subjects positive for Hepatitis C will be excluded. Subjects with anti-HBc positivity and DNA negative may be included but will be required to undergo monthly HBV DNA testing and liver function liver function testing (AST, ALT, alkaline phosphatase, total bilirubin). Patients with HCV antibody positivity and HCV pcr negativity are eligible to be included.
  8. * Subject requires the use of warfarin
  9. * Subject has received immunization with live virus vaccine within 28 days prior to the first dose of study drug
  10. * A female subject is pregnant or breast-feeding

Contacts and Locations

Principal Investigator

Lode Swinnen, MD
PRINCIPAL_INVESTIGATOR
Johns Hopkins School of Medicine

Study Locations (Sites)

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland, 21231
United States

Collaborators and Investigators

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

  • Lode Swinnen, MD, PRINCIPAL_INVESTIGATOR, Johns Hopkins School of Medicine

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2022-06-21
Study Completion Date2025-05-14

Study Record Updates

Study Start Date2022-06-21
Study Completion Date2025-05-14

Terms related to this study

Additional Relevant MeSH Terms

  • Mantle Cell Lymphoma